IMAB_OUT_1 [2025-04-14 11:37:28 -0400] 3523 Bytes | 966 tokens | Cum: 966 tkns (12.07% of 8k)
==========================================================================

We need a winner today and it's already 11:37:26 AM on Mon Apr 14, 2025 -0400 ... So let's find out if I-MAB American Depositary (IMAB) is going up or if it's going nowhere fast. So, I pulled together a bunch of data for you to look over real fast. It's at 0.8600 up from 0.6692. Is there something here we can get excited about? Help me analyze.

--- COMPANY PROFILE ---
Company: I-MAB American Depositary (IMAB)
IPO: 2020-01-17 (5 Years Ago)
Market Cap: $65,200,868
Shares Outstanding: 187,450,000
Exchange: XNAS
Description: I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).

Here’s the first list of news for I-MAB American Depositary:

C1 - Today 09:35AM - After Plunging -20.33% in 4 Weeks, Here's Why the Trend Might Reverse for IMab (IMAB)
C2 - Apr-11-25 09:35AM - After Plunging -19.7% in 4 Weeks, Here's Why the Trend Might Reverse for IMab (IMAB)
C3 - Apr-03-25 04:01PM - I-Mab Reports Full Year 2024 Financial Results and Provides Business Update
C4 - Mar-26-25 07:00AM - I-Mab to Present at 24th Annual Needham Virtual Healthcare Conference
C5 - Mar-21-25 04:30PM - I-Mab Announces Receipt Of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
C6 - Mar-07-25 07:00AM - I-Mab Announces Accelerated Givastomig Phase 1b Study Progress
C7 - Feb-18-25 07:00AM - I-Mab to Participate in Leerink Partners Global Healthcare Conference
C8 - Feb-04-25 07:30AM - I-Mab to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**. I am **ScanScor**, a unified document retrieval and report parser.
Your role is to examine all available company data and draw sound conclusions.
The company under analysis is: I-MAB American Depositary (IMAB).

2) To request information, refer to any listed documents using their reference codes.

3) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
At the end, you'll be prompted to return these data pairs:

1) BRIEF_SUMMARY[] -- Write a brief summary
2) MARKET_SCORE[] -- Assign a Market Score
3) PRICE_TARGET[] -- Set a price target
4) AI_RPT_HEADLINE[] -- Generate a headline for the article
5) SQUEEZE_POTENTIAL[] -- Potential for this stock to become an active short squeeze play
6) TAGS[] -- 1 to 4 words for SEO tags
7) STOCK_TYPE[] -- Describe the type of investor style suited to this stock
8) PRIMARY_CATALYST[] -- What you believe caused this stock to move today
9) SENTIMENT[] -- Mkt sentiment of the opportunity
10) IMPROVEMENT_SUGGESTION[] -- What can we do better
11) ETHICAL_RATING[] -- Rate alignment with long-term shareholder interests

Restrict the next response to just 3 tokes until it's time for the summary and data pairs at the end.
Request a document with its reference code(s), such as:
- `C1`, `C2`, `C3`, etc.
- To load more documents, reply with: `NEX`

News articles, SEC filings, and key metrics will be revealed in subsequent prompts.
Stay focused. Gather evidence. Continue until your conclusions are clear.

IMAB_OUT_3 [2025-04-14 11:37:32 -0400] 1106 Bytes | 324 tokens | Cum: 1292 tkns (16.15% of 8k)
==========================================================================

Showing C3 (chunk 1 of 15): C3:
**I-Mab Reports Full Year 2024 Financial Results and Provides Business Update**
Date: Apr-03-25 04:01PM
Source: (GlobeNewswire)
URL: https://www.globenewswire.com/news-release/2025/04/03/3055576/0/en/I-Mab-Reports-Full-Year-2024-Financial-Results-and-Provides-Business-Update.html

April 03, 2025 16:01 ET| Source:I-Mab BiopharmaI-Mab Biopharma

ROCKVILLE, Md., April 03, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced financial results for the full year ended December 31, 2024, and highlighted recent pipeline progress and business updates.

“The last year has been transformational for I-Mab. We successfully established a new model as a U.S.-based biotech company, divested all business operations in China, redefined our strate

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

IMAB_OUT_5 [2025-04-14 11:37:33 -0400] 1105 Bytes | 276 tokens | Cum: 1656 tkns (20.70% of 8k)
==========================================================================

Showing C3 (chunk 2 of 15): gy, strengthened our leadership team, reprioritized our pipeline and accelerated the development of our lead program, givastomig, a novel Claudin-18.2 targeted therapy,”said Sean Fu, PhD, MBA, CEO and board member of I-Mab.“We believe givastomig is uniquely situated to be a potential best-in-class, Claudin-18.2 therapy, with broad applicability in gastric cancer and beyond, and our strong cash balance positions us to build on the momentum.”

2024 Selected Finance and Corporate Development Highlights:

Pipeline Overview and Potential Upcoming Milestones

In January 2025, the Company announced a portfolio re-prioritization, with a focus on advancing its lead program, givastomig, a CLDN18.2 x 4-1BB bispecific antibody, targeting first-line (1L) metastatic gastric cancers, with further potential in other solid tumors. The Company continues to monitor development of uliledlimab, an antibody d

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

IMAB_OUT_7 [2025-04-14 11:37:33 -0400] 380 Bytes | 87 tokens | Cum: 1745 tkns (21.81% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

IMAB_OUT_9 [2025-04-14 11:37:35 -0400] 253 Bytes | 85 tokens | Cum: 1832 tkns (22.90% of 8k)
==========================================================================

Showing A1 (chunk 1 of 1): A1:
Document A1 not found. Only 0 articles available.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

IMAB_OUT_11 [2025-04-14 11:37:36 -0400] 776 Bytes | 270 tokens | Cum: 2157 tkns (26.96% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-04-03T20:01:00Z - I-Mab Reports Full Year 2024 Financial Results and Provides Business Update
B2 - 2024-05-23T21:05:00Z - I-Mab Announces Encouraging Phase 1 Clinical Data of PD-L1x4-1BB Bispecific Antibody Ragistomig at ASCO 2024
B3 - 2024-03-18T11:52:31Z - NVIDIA To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Monday
B4 - 2023-09-25T20:00:18Z - Expert Ratings for I-MAB
B5 - 2023-09-05T19:00:41Z - Where I-MAB Stands With Analysts
B6 - 2023-08-18T18:00:23Z - Analyst Ratings for I-MAB

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

IMAB_OUT_13 [2025-04-14 11:37:40 -0400] 780 Bytes | 224 tokens | Cum: 2383 tkns (29.79% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**I-Mab Reports Full Year 2024 Financial Results and Provides Business Update**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/04/03/3055576/0/en/I-Mab-Reports-Full-Year-2024-Financial-Results-and-Provides-Business-Update.htmlI-Mab, a U.S.-based biotech company, reported positive momentum in its Phase 1b combination trial for givastomig in first-line gastric cancer, with topline data expected in 2H 2025. The company has a strong financial position with $173.4 million in cash and cash equivalents, providing a runway into 2027.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

IMAB_OUT_15 [2025-04-14 11:37:41 -0400] 238 Bytes | 59 tokens | Cum: 2552 tkns (31.90% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

IMAB_OUT_17 [2025-04-14 11:37:41 -0400] 251 Bytes | 78 tokens | Cum: 2633 tkns (32.91% of 8k)
==========================================================================

You just read a chunk of S1.
You may now:
- Say "MOR" to continue this article
- Say "S2", "S3", etc. to request another
- Or say "NEX" to move to the next source

You are allowed up to 6 articles from this list. If you’re ready to move on, say NEX.

IMAB_OUT_19 [2025-04-14 11:37:49 -0400] 4887 Bytes | 1172 tokens | Cum: 3808 tkns (47.60% of 8k)
==========================================================================

This is our set of metrics for I-MAB American Depositary.
Please analyze the numbers.

+---------------------+-----------------------+-------------------------+-------------------------+
| Volume: 331,233 | Perf Month: 1.20% | Option/Short: Yes / Yes | Sales Y/Y TTM: -100.00% |
+---------------------+-----------------------+-------------------------+-------------------------+
| Avg Volume: 252.69K | Perf Quarter: -20.56% | Short Float: 0.42% | ROE: -22.38% |
+---------------------+-----------------------+-------------------------+-------------------------+
| Rel Volume: 4.06 | Index: - | Short Ratio: 1.30 | ROI: -27.67% |
+---------------------+-----------------------+-------------------------+-------------------------+
| RSI (14): 56.34 | Market Cap: 66.83M | Short Interest: 0.33M | Sales Surprise: - |
+---------------------+-----------------------+-------------------------+-------------------------+
| ATR (14): 0.08 | Shs Outstand: 78.62M | Beta: 1.20 | EPS Surprise: 16.67% |
+---------------------+-----------------------+-------------------------+-------------------------+
| SMA20: 8.31% | Shs Float: 78.41M | Sales Q/Q: 15398.08% | P/E: - |
+---------------------+-----------------------+-------------------------+-------------------------+
| SMA50: -1.59% | Inst Own: 15.34% | Sales past 5Y: 922.97% | Earnings: Apr 03 AMC |
+---------------------+-----------------------+-------------------------+-------------------------+
| SMA200: -22.32% | Insider Own: 0.27% | Employees: 32 | |
+---------------------+-----------------------+-------------------------+-------------------------+
| Perf Week: 37.10% | Insider Trans: 0.00% | Debt/Eq: 0.02 | |
+---------------------+-----------------------+-------------------------+-------------------------+

The next section covers any insider trading by I-MAB American Depositary officers or majority shareholders (if available).

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): N/A
Net Income: N/A
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 0.86
Average Volume: 237961.38
30-Day High: 0.889
30-Day Low: 0.62
No detailed financial data available.
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of I-MAB American Depositary (IMAB).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about I-MAB American Depositary.

2) MARKET_SCORE[]
This conversation was initiated because IMAB is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for IMAB.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, IMAB could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect IMAB to increase 50% from its current price of $0.86, say: PRICE_TARGET[1.29]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of I-MAB American Depositary.

11) ETHICAL_RATING[]
Rate I-MAB American Depositary’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

Return only: FIELD[value] for each of the above 11 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

IMAB_IN_21 [2025-04-14 11:37:49 -0400] 126 Bytes | 29 tokens | Cum: 4027 tkns (50.34% of 8k)
==========================================================================

====================================
[2025-04-14 11:37:49] # Analysis Completed
Elapsed Time: 22.68 seconds